NanoCellect Biomedical Completes $10M Series B Financing

NanoCellect Biomedical Inc., a San Diego, CA-based developer of microfluidic cell sorting technologies for cell-based assays, completed a $10m Series B financing round including convertible notes.

The financing included the participation of new investors Illumina Ventures, Anzu Partners, Vertical Venture Partners, and 5 Prime Ventures and existing investors FusionX Ventures and Agilent Technologies. In conjunction with the funding, Alexis Ji, Partner at Illumina Ventures, has joined NanoCellect’s Board of Directors.

The proceeds from this financing will enable the company to continue to expand its commercial activities and accelerate efforts in such application areas as cell line development, genomic sample preparation, CRISPR gene editing, and antibody discovery.

Led by Jose Morachis, Ph.D., President and Chief Executive Officer and co-founder, NanoCellect is a life science tools company manufacturing cell sorters that use proprietary microfluidic technology. The company’s WOLF cell sorter and N1 single cell plate dispenser aims to enable researchers to perform antibody discovery, cell line development, genomic sample preparation and CRISPR genomic editing faster, safer, and without contamination.



Join the discussion